APA (7th ed.) Citation

Liao, J., Yang, L., Zhou, L., Zhao, H., Qi, X., Cui, Y., & Ouyang, D. (2022). The NPC1L1 Gene Exerts a Notable Impact on the Reduction of Low-Density Lipoprotein Cholesterol in Response to Hyzetimibe: A Factorial-Designed Clinical Trial. Frontiers in pharmacology, 13, 755469. https://doi.org/10.3389/fphar.2022.755469

Chicago Style (17th ed.) Citation

Liao, Jianwei, Liyun Yang, Luping Zhou, Hongbin Zhao, Xiao Qi, Yimin Cui, and Dongsheng Ouyang. "The NPC1L1 Gene Exerts a Notable Impact on the Reduction of Low-Density Lipoprotein Cholesterol in Response to Hyzetimibe: A Factorial-Designed Clinical Trial." Frontiers in Pharmacology 13 (2022): 755469. https://doi.org/10.3389/fphar.2022.755469.

MLA (9th ed.) Citation

Liao, Jianwei, et al. "The NPC1L1 Gene Exerts a Notable Impact on the Reduction of Low-Density Lipoprotein Cholesterol in Response to Hyzetimibe: A Factorial-Designed Clinical Trial." Frontiers in Pharmacology, vol. 13, 2022, p. 755469, https://doi.org/10.3389/fphar.2022.755469.